Munro et al have demonstrated a salubrious effect of hydroxychloroquine (HCQ) on lipid profiles in patients with rheumatic arthritis (RA).1 In an accompanying editorial, Situnayake and Kitas highlight the potential importance of dyslipidaemia in RA.2 We concur with the relevance of this problem, and would like to call attention to some additional data that supports the authors’ points.

In an earlier study, we reported on the serum lipoprotein profiles of 60 men with RA.3 According to National Cholesterol Education Program guidelines,4 18% of the patients had dyslipidaemia to such an extent that …